A cell therapy method for the treatment of tumors
CA 2438754 C · Owner: Ortho-Mcneil-Janssen Pharmaceuticals, Inc. · Inventors: Moriarty, Ann; Peterson, Per A.; Jackson, Michael R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate stimulate and expand naïve , cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty allowing for efficient loading of , multiple peptides that …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 19, 2002 and granted October 7, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 19, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 19, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.